相似文献
1
Novel neuroprotectant chiral 3-n-butylphthalide inhibits tandem-pore-domain potassium channel TREK-1.
Acta Pharmacol Sin. 2011 Feb;32(2):182-7. doi: 10.1038/aps.2010.210.
2
Over-expressed human TREK-1 inhibits CHO cell proliferation via inhibiting PKA and p38 MAPK pathways and subsequently inducing G1 arrest.
Acta Pharmacol Sin. 2016 Sep;37(9):1190-8. doi: 10.1038/aps.2016.65. Epub 2016 Jul 11.
3
An increased TREK-1-like potassium current in ventricular myocytes during rat cardiac hypertrophy.
J Cardiovasc Pharmacol. 2013 Apr;61(4):302-10. doi: 10.1097/FJC.0b013e318280c5a9.
4
Inhibition of human TREK-1 channels by bupivacaine.
Anesth Analg. 2003 Jun;96(6):1665-1673. doi: 10.1213/01.ANE.0000062524.90936.1F.
5
Protective effects of TREK-1 against oxidative injury induced by SNP and H2O2.
Acta Pharmacol Sin. 2008 Oct;29(10):1150-6. doi: 10.1111/j.1745-7254.2008.00853.x.
6
Lig4-4 selectively inhibits TREK-1 and plays potent neuroprotective roles in vitro and in rat MCAO model.
Neurosci Lett. 2018 Apr 3;671:93-98. doi: 10.1016/j.neulet.2018.02.015. Epub 2018 Feb 10.
7
TWIK-1 and TREK-1 are potassium channels contributing significantly to astrocyte passive conductance in rat hippocampal slices.
J Neurosci. 2009 Jul 1;29(26):8551-64. doi: 10.1523/JNEUROSCI.5784-08.2009.
8
Inhibition of human TREK-1 channels by caffeine and theophylline.
Epilepsy Res. 2005 May;64(3):127-35. doi: 10.1016/j.eplepsyres.2005.03.002.
9
Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
Br J Pharmacol. 2011 Jul;163(5):1099-110. doi: 10.1111/j.1476-5381.2011.01319.x.
10
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1003-16. doi: 10.1007/s00210-012-0780-9. Epub 2012 Jul 13.
引用本文的文献
1
Regulation of Blood-Brain Barrier Permeability via JNK Signaling Pathway: Mechanisms and Potential Therapeutic Strategies for Ischemic Stroke, Alzheimer's Disease and Brain Tumors.
Molecules. 2025 May 28;30(11):2353. doi: 10.3390/molecules30112353.
2
Haplotype-phased genome unveils the butylphthalide biosynthesis and homoploid hybrid origin of .
Sci Adv. 2024 Feb 9;10(6):eadj6547. doi: 10.1126/sciadv.adj6547. Epub 2024 Feb 7.
3
The Two-Pore Domain Potassium Channel TREK-1 Promotes Blood-Brain Barrier Breakdown and Exacerbates Neuronal Death After Focal Cerebral Ischemia in Mice.
Mol Neurobiol. 2022 Apr;59(4):2305-2327. doi: 10.1007/s12035-021-02702-5. Epub 2022 Jan 24.
4
Structural Insights into the Mechanisms and Pharmacology of K Potassium Channels.
J Mol Biol. 2021 Aug 20;433(17):166995. doi: 10.1016/j.jmb.2021.166995. Epub 2021 Apr 20.
5
Role of TREK-1 in Health and Disease, Focus on the Central Nervous System.
Front Pharmacol. 2019 Apr 11;10:379. doi: 10.3389/fphar.2019.00379. eCollection 2019.
6
Dl-3n-butylphthalide reduces epileptiform activity through GluA2-lacking calcium-permeable AMPARs in epilepsy models.
Oncotarget. 2017 Oct 5;8(58):98242-98257. doi: 10.18632/oncotarget.21529. eCollection 2017 Nov 17.
7
Effects of Dl-3-n-butylphthalide on Cerebral Ischemia Infarction in Rat Model by Mass Spectrometry Imaging.
Int J Mol Sci. 2017 Nov 22;18(11):2451. doi: 10.3390/ijms18112451.
8
Dl-3-n-butylphthalide protects the heart against ischemic injury and H9c2 cardiomyoblasts against oxidative stress: involvement of mitochondrial function and biogenesis.
J Biomed Sci. 2017 Jun 15;24(1):38. doi: 10.1186/s12929-017-0345-9.
9
A Review of Recent Advances in Neuroprotective Potential of 3-N-Butylphthalide and Its Derivatives.
Biomed Res Int. 2016;2016:5012341. doi: 10.1155/2016/5012341. Epub 2016 Dec 8.
10
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015.
Acta Pharm Sin B. 2016 Nov;6(6):522-530. doi: 10.1016/j.apsb.2016.06.013. Epub 2016 Jul 28.
本文引用的文献
1
Molecular mechanisms underlying membrane-potential-mediated regulation of neuronal K2P2.1 channels.
Mol Cell Neurosci. 2010 Jan;43(1):117-26. doi: 10.1016/j.mcn.2009.10.002. Epub 2009 Oct 24.
2
TWIK-1 and TREK-1 are potassium channels contributing significantly to astrocyte passive conductance in rat hippocampal slices.
J Neurosci. 2009 Jul 1;29(26):8551-64. doi: 10.1523/JNEUROSCI.5784-08.2009.
3
Analysis of astroglial K+ channel expression in the developing hippocampus reveals a predominant role of the Kir4.1 subunit.
J Neurosci. 2009 Jun 10;29(23):7474-88. doi: 10.1523/JNEUROSCI.3790-08.2009.
4
Long-term treatment of l-3-n-butylphthalide attenuated neurodegenerative changes in aged rats.
Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):565-74. doi: 10.1007/s00210-009-0398-8. Epub 2009 Feb 12.
5
Two-pore potassium channels in the cardiovascular system.
Eur Biophys J. 2009 Mar;38(3):305-18. doi: 10.1007/s00249-008-0326-8. Epub 2008 May 1.
6
l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells.
Neurosci Lett. 2008 Mar 28;434(2):224-9. doi: 10.1016/j.neulet.2008.01.080. Epub 2008 Feb 14.
7
Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.
Med Hypotheses. 2008;70(3):548-50. doi: 10.1016/j.mehy.2007.06.030. Epub 2007 Aug 20.
8
Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists.
J Pharmacol Exp Ther. 2007 Oct;323(1):39-48. doi: 10.1124/jpet.107.125245. Epub 2007 Jul 10.
9
The neuronal background K2P channels: focus on TREK1.
Nat Rev Neurosci. 2007 Apr;8(4):251-61. doi: 10.1038/nrn2117.
10
Modulation of potassium channels as a therapeutic approach.
Curr Pharm Des. 2006;12(4):459-70. doi: 10.2174/138161206775474477.
Zotero 插件